BTAI earnings date and last-quarter result: last quarter beat, P/E -0.13. Updated 2026-07-23.
BioXcel Therapeutics (BTAI) Research Hub
BioXcel Therapeutics (BTAI) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-01, shares last closed at 0.045 USD (+4.65%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.13, market cap 0.03B. This hub links to the full technical, earnings and options research available for BTAI.
Last updated 2026-10-01 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 0.045 USD (+4.65%) |
| 52-week range | 0.019 USD – 1.43 USD |
| Trend regime | Range |
| 14-day RSI | 23.2 (Oversold) |
| Trailing P/E | -0.13 |
| Market cap | 0.03B |
| Dividend yield | 0.00% |
Available research for BTAI
Covered Call on BTAI: how it works, illustrative setup around the real 0.045 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on BTAI: how it works, illustrative setup around the real 0.045 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on BTAI: how it works, illustrative setup around the real 0.045 USD price, max profit/loss, breakeven and when to use it. Educational.
BTAI technical analysis: range, last 0.045 USD, RSI 23.2, 52w range 0.019 USD–1.43 USD, real support/resistance. Updated 2026-10-01.
More on SniperIQ
Frequently asked questions
What sector is BTAI in?
BioXcel Therapeutics (BTAI) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is BTAI in an uptrend or downtrend?
As of 2026-10-01, BTAI is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is BTAI's trailing P/E ratio?
BTAI's trailing P/E is -0.13, with a market cap of 0.03B. See the earnings research page for full valuation detail.